Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Northern Trust Corp

Northern Trust Corp cut its position in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 8.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 45,211 shares of the company’s stock after selling 4,220 shares during the period. Northern Trust Corp’s holdings in Vistagen Therapeutics were worth $133,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. R Squared Ltd acquired a new position in Vistagen Therapeutics during the fourth quarter worth $25,000. Boothbay Fund Management LLC purchased a new position in Vistagen Therapeutics during the fourth quarter worth $66,000. Prosperity Wealth Management Inc. purchased a new position in Vistagen Therapeutics during the fourth quarter worth $86,000. Landscape Capital Management L.L.C. purchased a new position in Vistagen Therapeutics during the fourth quarter worth $123,000. Finally, Blair William & Co. IL increased its position in Vistagen Therapeutics by 11.3% during the fourth quarter. Blair William & Co. IL now owns 98,466 shares of the company’s stock worth $290,000 after buying an additional 10,000 shares in the last quarter. 78.39% of the stock is owned by institutional investors and hedge funds.

Vistagen Therapeutics Stock Performance

Vistagen Therapeutics stock opened at $2.39 on Wednesday. The stock has a fifty day moving average of $2.30 and a two-hundred day moving average of $2.60. The company has a market capitalization of $68.98 million, a price-to-earnings ratio of -1.61 and a beta of 0.67. Vistagen Therapeutics, Inc. has a fifty-two week low of $1.90 and a fifty-two week high of $4.21.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.